Compare Cassava Sciences Inc (FLNA) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.95. The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SJNK | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Sector/Thematic |
52-Week High | $4.64 | $25.63 |
52-Week Low | $1.09 | $24.75 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SJNK trades at $24.945, up 0.14% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains consistent monthly dividend distributions, including recent payments of $0.14 and $0.15 per share. Recent news highlights institutional accumulation by Berkshire Money Management but cautions on high-yield bond exposure amid economic uncertainty.
Outlook remains cautious due to bearish technical indicators and analyst skepticism about high-yield bond sustainability. Risks include interest rate sensitivity and credit spread volatility, while the dividend yield offers income appeal. Investors should weigh income stability against potential capital depreciation in a tightening cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
